Association of serum interleukin-5 and interleukin-13 levels with different obesity phenotypes
LIU Ning1,2, ZHUANG Si-qi1, FU Yao-yang1, TANG Ling-li1, TANG Hao-neng1
1. The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China; 2. School of Medicine, Yueyang Vocational and Technical College, Yueyang, Hunan 414000, China
Abstract：Objective To explore the relationship of serum interleukin-5 (IL-5) and interleukin-13 (IL-13) levels withdifferent obesity phenotypes so as to provide new ideas for prevention and control of obesity and related metabolic diseases. Methods The obese were selected from people underwent physical examination in the Second Xiangya Hospital of Central South University from November 2018 to April 2019, and all of them were divided into the metabolically unhealthy obesity (MUO) group and the metabolically healthy obesity (MHO) group (each n=72) according to the abnormality of metabolism. During the same period, 73 persons who had normal body weight and metabolism and were gender- and age-matched with the obese were selected as the healthy control (HC) group. The serum levels of IL-5 and IL-13 were measured. The logistic regression was used to analyze the association of the two cytokines with different obese phenotypes, and the stepwise linear regression analysis was performed to identify the main factors influencing the two cytokines. Results There was a statistically significant difference in the comparison of IL-13 between the MHO group and the HC group (P<0.05), but no statistically significant difference was found in the comparison of IL-5 between the two groups. The serum levels of IL-5 and IL-13 in the MUO group increased significantly, showing statistically significant differences as compared with the MHO group and the HC group (both P<0.05). Serum IL-5 and IL-13 levels were not significantly correlated with MHO phenotype, but significantly and positively correlated with MUO phenotype. Every time IL-5 increased 2 pg/ml, the odds ratio of MUO phenotype increased by 81% (OR=1.81, 95%CI:1.40-2.35, P<0.0001). Every time IL-13 increased 10 pg/ml, the odds ratio of MUO phenotype increases by 5% (OR=1.05, 95%CI:1.03-1.07, P<0.0001). Multiple linear stepwise regression analysis showed that systolic blood pressure (β=0.296, P=0.000) and fasting plasma glucose (β=0.217, P=0.008) were the independent factors influencing the level of IL-5, while waist circumference (β=0.186, P=0.018) and uric acid (β=0.200, P=0.019) were the independent factors influencing IL-13. Conclusions IL-5 and IL-13 have no significant correlation with MHO phenotype, but have significantly positive correlation with MUO phenotype. The two cytokines may play different roles in the occurrence and development of obesity.
柳宁, 庄思琪, 付瑶阳, 唐玲丽, 唐浩能. 白介素-5和白介素-13血清水平与不同肥胖表型的关联分析[J]. 实用预防医学, 2020, 27(10): 1176-1181.
LIU Ning, ZHUANG Si-qi, FU Yao-yang, TANG Ling-li, TANG Hao-neng. Association of serum interleukin-5 and interleukin-13 levels with different obesity phenotypes. , 2020, 27(10): 1176-1181.
[1] GBD 2015 Obesity Collaborators.Health effects of overweight and obesity in 195 countries over 25 years[J].N Engl J Med, 2017, 377(1):13-27. [2] Lee BC, Lee J.Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance[J].Biochim Biophys Acta, 2014, 1842(3):446-462. [3] 徐继英,严青华,姚海宏.上海市成年人中心性肥胖者糖尿病的患病风险[J].实用预防医学,2018,25(7):810-813. [4] 马海燕.代谢综合征及其研究进展[J].医学理论与实践,2010,23(7):792-794. [5] Sims EAH.Are there persons who are obese, but metabolically healthy?[J].Metabolism, 2001, 50(12):1499-1504. [6] Pajunen P, Kotronen A, Korpi-Hyvlti E, et al.Metabolically healthy and unhealthy obesity phenotypes in the general population: the FIN-D2D survey[J].BMC Public Health, 2011, 11(1):754. [7] Karelis AD, Faraj M, Bastard JP, et al.The metabolically healthy but obese individual presents a favorable inflammation profile[J].J Clin Endocrinol Metab, 2005, 90(7):4145-4150. [8] Teixeira TFS, Alves RDM, Moreira APB, et al.Main characteristics of metabolically obese normal weight and metabolically healthy obese phenotypes[J].Nutr Rev, 2015, 73(3):175-190. [9] Camhi SM, Katzmarzyk PT.Differences in body composition between metabolically healthy obese and metabolically abnormal obese adults[J]. Int J Obes(Lond), 2014, 38(8):1142-1145. [10] Magkos F.Metabolically healthy obesity: what's in a name?[J].Am J Clin Nutr NLM, 2019, 110(3):533-539. [11] Spencer LA, Weller PF.Eosinophils and Th2 immunity: contemporary insights[J].Immunol Cell Biol, 2010, 88(3):250-256. [12] Knutsson A, Bjrkbacka H, Dunér P, et al.Associations of interleukin-5 with plaque development and cardiovascular events[J].JACC: Basic Transl Sci, 2019, 4(8):891-902. [13] Madhumitha H, Mohan V, Deepa M, et al.Increased Th1 and suppressed Th2 serum cytokine levels in subjects with diabetic coronary artery disease[J].Cardiovasc Diabetol, 2014, 13(1):1. [14] Darkhal P, Gao M, Ma Y, et al.Blocking high-fat diet-induced obesity, insulin resistance and fatty liver by overexpression of Il-13 gene in mice[J].Int J Obes, 2015, 39(8):1292-1299. [15] Rütti S, Howald C, Arous C, et al.IL-13 improves beta-cell survival and protects against IL-1beta-induced beta-cell death[J].Mol Metab, 2016, 5(2):122-131. [16] Stanya KJ, Jacobi D, Liu S, et al.Direct control of hepatic glucose production by interleukin-13 in mice[J].J Clin Invest, 2013, 123(1):261-271. [17] Schmidt FM, Weschenfelder J, Sander C, et al.Inflammatory cytokines in general and central obesity and modulating effects of physical activity[J].PLoS One, 2015, 10(3):e0121971. [18] Lucas R, Parikh SJ, Sridhar S, et al.Cytokine profiling of young overweight and obese female African American adults with prediabetes[J].Cytokine, 2013, 64(1):310-315. [19] Surendar J, Mohan V, Rao MM, et al.Increased levels of both Th1 and Th2 cytokines in subjects with metabolic syndrome(CURES-103)[J].Diabetes Technol Ther, 2011, 13(4):477-482. [20] Martínez-Reyes CP, Gómez-Arauz AY, Torres-Castro I, et al.Serum levels of interleukin-13 increase in subjects with insulin resistance but do not correlate with markers of low-grade systemic inflammation[J].J Diabetes Res, 2018, 2018(1):7209872. [21] Ahmad R, Al-Roub A, Koshy M, et al.Relationship of Il-5 with Th1 and Th2 cytokines in individuals with or without type-2 diabetes[J].J Glycomics Lipidomics, 2015, 5(4):1. [22] Xu J, Ehrman B, Graham LM, et al. Interleukin-5 is a potential mediator of angiotensin II-induced aneurysm formation in apolipoprotein E knockout mice[J]. J Surg Res, 2012, 178(1):512-518. [23] Bucher F, Lee J, Shin S, et al.Interleukin-5 suppresses vascular endothelial growth factor-induced angiogenesis through STAT5 signaling[J].Cytokine, 2018, 110(1):397-403. [24] Kwon H, Laurent S, Tang Y, et al.Adipocyte-specific IKKβ signaling suppresses adipose tissue inflammation through an IL-13-dependent paracrine feedback pathway[J].Cell Rep, 2014, 9(5):1574-1583. [25] Anand G, Vasanthakumar R, Mohan V, et al.Increased IL-12 and decreased IL-33 serum levels are associated with increased Th1 and suppressed Th2 cytokine profile in patients with diabetic nephropathy(CURES-134)[J].Int J Clin Exp Pathol, 2014, 7(11):8008.
2020, Vol. 27 
